These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
447 related items for PubMed ID: 21538383
1. Long-term outcomes of sirolimus-eluting stents vs. paclitaxel-eluting stents in unprotected left main coronary artery bifurcation lesions. Song PS, Ryu DR, Song YB, Hahn JY, Choi JH, Choi SH, Lee SH, Hong KP, Park JE, Gwon HC. Clin Cardiol; 2011 Jun; 34(6):378-83. PubMed ID: 21538383 [Abstract] [Full Text] [Related]
2. Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion. Kim U, Kim DK, Seol SH, Yang TH, Kim DK, Kim DI, Kim DS, Lee SH, Hong GR, Park JS, Shin DG, Kim YJ, Cho YK, Kim HS, Nam CW, Hur SH, Kim KB. Clin Cardiol; 2010 Jun; 33(6):340-4. PubMed ID: 20556803 [Abstract] [Full Text] [Related]
8. Sirolimus- versus paclitaxel-eluting stents for coronary bifurcations intervention: a meta-analysis of five clinical trials. Qian J, Chen Z, Ma J, Ge J. Catheter Cardiovasc Interv; 2012 Oct 01; 80(4):507-13. PubMed ID: 22045690 [Abstract] [Full Text] [Related]
10. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Kang SJ, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Kim HS, Park SJ. JACC Cardiovasc Interv; 2011 Mar 01; 4(3):310-6. PubMed ID: 21435609 [Abstract] [Full Text] [Related]
11. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW. JACC Cardiovasc Interv; 2011 Nov 01; 4(11):1209-15. PubMed ID: 22115661 [Abstract] [Full Text] [Related]
13. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, Leon MB. JACC Cardiovasc Interv; 2011 May 01; 4(5):543-50. PubMed ID: 21596327 [Abstract] [Full Text] [Related]
17. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease. Simsek C, Onuma Y, Magro M, de Boer S, Battes L, van Domburg RT, Boersma E, Serruys PW, Interventional Cardiologists of the Thoraxcenter (2000-2005). Catheter Cardiovasc Interv; 2010 Jul 01; 76(1):41-9. PubMed ID: 20310019 [Abstract] [Full Text] [Related]